Several actionable gene alterations, such as EGFR and KRAS mutations, for lung cancer are different in frequency between Caucasian and East Asian. NTRK fusions have been recently identified as a therapeutic target in a rare fraction of Caucasian patients with lung adenocarcinoma (3.3%). However, their frequency in East Asian has not yet been examined.
A nationwide lung cancer genomic screening project in Japan (LC-SCRUM-Japan) was initiated from February 2013, and a total of 4118 lung cancer patients have been enrolled as of April 2017. A total of 2668 patients with lung cancer (non-squamous/squamous/small=2088/275/305) were screened by using a next generation sequencing platform, Oncomine™ Focus Assay (OFA) for detecting NTRK1/2/3 fusions or Oncomine™ Comprehensive Assay (OCA) for detecting NTRK1/3 fusions.
Only one patient with ETV6-NTRK3 fusion (0.04%) was detected. The patient harboring ETV6-NTRK3 fusion was a 60-year-old man with a 35 pack-year smoking history, and pathologically diagnosed with adenocarcinoma. We also evaluated NTRK1 gene fusion–induced imbalances in the expression of the 5’ and 3’ regions of the transcripts using the OFA sequencing data, and there was no case with 5’/3’ expression imbalances of NTRK1 gene transcripts.
The frequency of NTRK fusions in Japanese patients with lung cancer is extremely rare (0.04%) compared with Caucasian.
Clinical trial identification
Legal entity responsible for the study
National Cancer Center
Taiho, Chugai, Ono, Astra Zeneka, Bristol-Myers Squibb, MSD, Astellas, Eisai, DAIICHI SANKYO, Pfizer, Kyowa Hakko Kirin, Novartis, Takeda, Eli Lilly Japan, Merck Serono, Boehringer Ingelheim, Amgen
T. Hida: Ignyta, Y. Ohe: HONORARIA: AstraZeneca, Chugai, Lilly, ONO, BMS, Daiichi-Sankyo, Nipponkayaku, Boehringer Ingelheim, Bayer, Pfizer, MSD, Taiho RESEARCH FUNDING: AstraZeneca, Chugai, Lilly, ONO, BMS, Kyorin, Dainippon- Sumitomo, Pfizer, Taiho, Novartis, Merck Serono, CONSULTING OR ADVISORY ROLE: AstraZeneca, Chugai, Lilly, ONO, Novartis, S. Kuyama: HONORARIA: AstraZeneca, Meiji Seika, Boehringer Ingelheim, Lilly, Chugai, ONO, MSD, K. Yoh: Dr. Yoh has received personal fees as honoraria from Chugai, Eli Lilly, AstraZeneca, Taiho, Boehringer Ingelheim, Bristol-Myers Squibb, and Ono. His institution has received research funding from Pfizer, Taiho, Eli Lilly, AstraZeneca, Bayer and Novartis. K. Goto: Corporate-sponsored research: Taiho, Chugai, Ono, Astra Zeneka, Sumitomo Dainippon, Bristol-Myers Squibb, MSD, Astellas, Eisai, DAIICHI SANKYO, Pfizer, Kyowa Hakko Kirin, Novartis, Takeda, Eli Lilly Japan, Merck Serono, OxOnc, AbbVie Stemcentrx, Ignyta, Boehringer Ingelheim
All other authors have declared no conflicts of interest.